Business
Milestone Scientific Reports Financial Results for First Quarter 2026
Operating Loss Reduced As Company Advances Toward Profitability Reaffirms Outlook for Double-Digit Revenue Growth in 2026, including Significant Growth in CompuFlo® Sales ROSELAND, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the three months ended March 31, 2026. “Our first quarter resul
About this update from Milestone Scientific, Inc.
[{"type":"image","alt":"Milestone Scientific, Inc.","displaySize":"","headline":null,"caption":"Milestone Scientific, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":65,"url":"https://media.zenfs.com/en/globenewswire.com/2153125b7314814c812953238fb1ca11"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pYAYMPxRv4_7h7yMj8t5mg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkx/https://media.zenfs.com/en/globenewswire.com/2153125b7314814c812953238fb1ca11","width":300,"height":65},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/pYAYMPxRv4_7h7yMj8t5mg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkx/https://media.zenfs.com/en/globenewswire.com/2153125b7314814c812953238fb1ca11","width":300,"height":65}},"lazy":false},{"type":"text","content":"Operating Loss Reduced As Company Advances Toward Profitability","length":63,"tagName":"p"},{"type":"text","content":"Reaffirms Outlook for Double-Digit Revenue Growth in 2026, including Significant Growth in CompuFlo® Sales","length":106,"tagName":"p"},{"type":"text","content":"ROSELAND, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the three months ended March 31, 2026.","length":304,"tagName":"p"},{"type":"text","content":"“Our first quarter results reflect continued progress as we execute on the foundation established in 2025,” said Eric Hines, Chief Executive Officer of Milestone Scientific. “We delivered meaningful improvements in operating efficiency, reducing expenses by more than 30% and significantly narrowing our operating loss, while maintaining a relatively stable revenue base in a dynamic market environment, though revenue was impacted by challenges shipping certain booked orders to the Middle East due to the ongoing conflict in the region. Importantly, our medical business continued to gain traction, with revenue more than doubling year-over-year, reflecting early-stage adoption of our technology and growing interest from clinicians.","length":736,"tagName":"p"},{"type":"text","content":"“Following the quarter, we strengthened our balance sheet through a $2.15 million financing, providing additional flexibility to invest in key growth initiatives, including sales expansion...